Previous Article | Next Article ![]()
J Virol, June 1998, p. 4858-4865, Vol. 72, No. 6
Division of Infectious Diseases, Department
of Medicine, Case Western Reserve University, Cleveland, Ohio
44106,1 and
McGill AIDS Centre, Lady
Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada
H3T 1E22
Received 20 January 1998/Accepted 20 March 1998
Difficulties in deciphering the mechanisms of
3'-azido-3'-deoxythymidine (AZT)-resistance by human immunodeficiency
virus type 1 (HIV-1) variants are due in part to an inability to
reconstitute resistance in vitro using AZT-resistant reverse
transcriptases. We decided to characterize mechanisms of AZT resistance
in tissue culture infections by studying the ability of drug-resistant
viruses to synthesize viral DNA in the presence or absence of drug.
Through use of PCR amplifications, we discovered an AZT-mediated
stimulation of reverse transcription by AZT-resistant viruses carrying
the M41L and T215Y mutations that can apparently override the
inhibitory effects of AZT-5'-triphosphate. In addition, the presence of
AZT also causes viruses containing the M41L and T215Y substitutions to
have diminished sensitivity to other nucleoside analogs (i.e., ddC,
ddI, and d4T). This AZT-mediated cross-resistance may help to explain
the virological failure of treatment regimens that included ddI plus
AZT or ddC plus AZT in situations in which the T215Y and/or M41L
mutations were present (F. Brun-Vézinet, C. Boucher, C. Loveday,
D. Descamps, V. Fauveau, J. Izopet, D. Jeffries, S. Kaye, C. Krzyanowski, A. Nunn, R. Schuurman, J. M. Seigneurin, C. Tamalet,
R. Tedder, J. Weber, and G. J. Weverling, Lancet
350:983-990, 1997). Our results suggest that the use of AZT may be
contraindicated in those patients for whom resistance to this compound
(M41L and/or T215Y) has been demonstrated.
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
3'-Azido-3'-Deoxythymidine (AZT) Mediates Cross-Resistance to
Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency
Virus Type 1 Variants
*
Corresponding author. Mailing address: Division of
Infectious Diseases, BRB 1029, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106. Phone: (216) 368-8904. Fax: (216)
368-2034. E-mail: eja3{at}po.cwru.edu.
This article has been cited by other articles:
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»